¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) Á¦47Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦7Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º 2 : 2021-06-18

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) Á¦47Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦7Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º 2 : 2021-06-18
±³À°ÀÏÀÚ : 2021-06-18
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°(½Ç½Ã°£ È­»ó °­ÀÇ)  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) Á¦47Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦7Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º 2
ÁÖÃÖ±â°ü : ´ëÇѾÏÇÐȸ
´ã´çÀÚ : ÀÌÈñ¿¬
¿¬¶ôó : 02-792-1486  
À̸ÞÀÏ : cancer2@kams.or.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, ¼ºÇü¿Ü°ú, ¾È°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, ºñ´¢ÀÇÇаú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, ÀçÈ°ÀÇÇаú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаú¿¹¹æÀÇÇÐ, ÇغÎÇÐ, »ý¸®ÇÐ, »ýÈ­ÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀοø : 900¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 15 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 90,000¿ø      
ºñ°í 1. ȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 6¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 3¸¸¿ø / 3) ¾÷ü ¹× ¾÷ü¿¬±¸¼Ò: 6¸¸¿ø 2. ºñȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 9¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 4¸¸¿ø / 3) ¾÷ü ¹× ¾÷ü¿¬±¸¼Ò: 9¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-18 Room A 09:40~10:20 Dissecting tumor evolution  Tyler E. Jacks(Koch Institute for Integrative Cancer Research at MIT) 
È޽Ġ06-18  10:20~10:30 È޽Ġ () 
±³À°½Ã°£ 06-18 Room A 10:30~10:55 Addressing emerging challenges in cell therapy of cancer  Dario Campana(National University of Singapore Yong Loo Lin School of Medicine) 
±³À°½Ã°£ 06-18 Room A 10:55~11:20 Effects of sequential and timely combination of a cancer nanovaccine with immune checkpoint blockade on tumor control  Àü»ó¿ë(KAIST) 
±³À°½Ã°£ 06-18 Room A 11:20~11:45 Cancer immunotherapy targeting the tumor microenvironment by recombinant cytokine and bispecific antibody  À̽¿ì(POSTECH) 
±³À°½Ã°£ 06-18 Room A 11:45~12:10 Reprogrammed oncolytic adenovirus as cancer immunotherapeutic  À±Ã¤¿Á(ÇѾç´ë) 
±³À°½Ã°£ 06-18 Room B 10:30~10:55 Fluorescent-guided cancer surgery  Takeaki Ishizawa(University of Tokyo) 
±³À°½Ã°£ 06-18 Room B 10:55~11:20 Intraoperative radiotherapy for pancreas cancer  ¹ÚÁؼº(°­³²¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 06-18 Room B 11:20~11:45 AI prediction model for clinical outcomes of colorectal cancer  ¹ÚÁö¿ø(¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 06-18 Room B 11:45~12:10 AI Imaging analysis of surgical video  Á¤Ã¢¿í(¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 06-18 Room C 10:30~10:55 Proton therapy: What we know and do not know  ¿Àµ¿·Ä(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 06-18 Room C 10:55~11:20 Introduction of FLASH radiotherapy: KIRAMS experiences  Àå¿øÀÏ(¿øÀڷº´¿ø) 
±³À°½Ã°£ 06-18 Room C 11:20~11:45 Current technical challenges for FLASH proton therapy  ÀÓ¿µ°æ(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 06-18 Room C 11:45~12:10 Synchrotron X-ray FLASH therapy  ±èÁ¾±â(´ë±¸°¡Å縯ÀÇ´ë) 
½Ä»ç 06-18  12:10~12:50 ½Ä»ç  () 
±³À°½Ã°£ 06-18 Room A 12:50~13:10 To be announced  ÇÑÇý¼÷(ÃæºÏÀÇ´ë) 
±³À°½Ã°£ 06-18 Room B 12:50~13:10 TAS-102, for better treatment outcomes in metastatic colorectal cancer  ¹ü½ÂÈÆ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06-18 Room C 12:50~13:10 IMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC  ÀÌ´ëÈ£(¿ï»êÀÇ´ë) 
È޽Ġ06-18  13:10~13:20 È޽Ġ () 
±³À°½Ã°£ 06-18 Room A+B 13:20~13:45 Recent updates in COVID-19 treatment and vaccines  ÃÖÆò±Õ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-18 Room A+B 13:45~14:10 Special risk of COVID-19 in cancer surgery  Vivian E. Strong(Memorial Sloan Kettering Cancer Center) 
±³À°½Ã°£ 06-18 Room A+B 14:10~14:35 COVID-19 vaccination recommendation for cancer patients  ¹Ú¿¬Èñ(¼º±Õ°üÀÇ´ë) 
Åä·Ð 06-18 Room A+B 14:35~15:00 Panel Discussion: Influence of COVID-19 on cancer care in Asian countries  () 
±³À°½Ã°£ 06-18 Room C 13:20~13:45 Diagnosis and molecular classification of endometrial cancer  ±èÈ¿Áø(ºÐ´ç¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 06-18 Room C 13:45~14:10 Treatment decision according to the integrated molecular markers  ±è¹Ì°æ(ÀÌ´ë¸ñµ¿º´¿ø) 
±³À°½Ã°£ 06-18 Room C 14:10~14:35 Immune checkpoint inhibitor for recurrent setting  ¹®¿ëÈ­(Â÷ÀÇ´ë) 
±³À°½Ã°£ 06-18 Room C 14:35~15:00 Immune checkpoint blockade combination in endometrial cancer  È«ÁøÈ­(°í·ÁÀÇ´ë) 
È޽Ġ06-18  15:00~15:10 È޽Ġ () 
±³À°½Ã°£ 06-18 Room C 15:10~15:35 [º¸°Çº¹ÁöºÎ] K-Cancer ÅëÇÕ ºòµ¥ÀÌÅÍ ±¸Ãà ¹æ¾È°ú Àü·«  °­ÁØ(º¸°Çº¹ÁöºÎ) 
±³À°½Ã°£ 06-18 Room C 15:35~16:00 [±¹¸³¾Ï¼¾ÅÍ] ¾Ï ºòµ¥ÀÌÅÍ È°¿ë ÀÎÇÁ¶ó ±¸Ãà »ç¾÷ ÇöȲ  Ãֱͼ±(±¹¸³¾Ï¼¾Åͱ¹Á¦¾Ï´ëÇпø´ëÇб³) 
±³À°½Ã°£ 06-18 Room C 16:00~16:25 [±¹¹Î°Ç°­º¸Çè°ø´Ü] ¾Ï°ËÁø µ¥ÀÌÅÍ ÇöȲ ¹× È°¿ë  ±èµ¿¿í(±¹¹Î°Ç°­º¸Çè°ø´Ü) 
±³À°½Ã°£ 06-18 Room C 16:25~16:50 [K-MASTER] ¾ÏÀ¯Àüü ¹× ÀÓ»ó µ¥ÀÌÅÍ °ø°³ ¹× °øÀ¯  ¹Ú°æÈ­(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 06-18 Room A 15:10~15:35 Molecular characterization of responders and nonresponders to anti-PD1 inhibitors in GC  ÀÌÁö¿¬(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 06-18 Room A 15:35~16:00 Overcoming resistance to anti-HER2 therapy  ±èÅ¿ë(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-18 Room A 16:00~16:25 Strategies to overcome therapeutic resistance in renal cell carcinoma  ±èÀÎÈ£(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 06-18 Room A 16:25~16:50 Overcoming resistance to immunotherapy in combination with radiotherapy targeting the tumor microenvironment  ÀåÁö¼®(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06-18 Room B 15:10~15:35 Basic principles of AI in cancer imaging  ±èÈÖ¿µ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06-18 Room B 15:35~16:00 AI in neuro-oncology imaging  ¹ÚÁöÀº(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 06-18 Room B 16:00~16:25 AI approach in digital pathology  Á¤¿ä¼Á(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 06-18 Room B 16:25~16:50 Whole-slide image analysis reveals quantitative landscape of tumor–immune microenvironment in colorectal cancers  ¹èÁ¤¸ð(¼­¿ï´ëº´¿ø) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) Á¦47Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦7Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º 2 : 2021-06-18""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) 2021³â °áÇÙ°ü¸®±³À° 3±â (6¿ù 18ÀÏ) : 2021-06-18
´ÙÀ½±Û ¼¼ºê¶õ½ºº´¿ø (¿Â¶óÀÎ) ¾È°ú ±Ý¿äÁý´ãȸ(OCT angiography in glaucoma) : 2021-06-18
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20634 ´ëÀü 2024³â ´ëÀü±¤¿ª½ÃÀÇ»çȸ Ãá°èÇмú´ëȸ : 2024-05-18 0 5 2024-05-10
20633 ¼­¿ï ´ëÇѾȽŰæÀÇÇÐȸ Neurology of eye movements : 2024-05-18 0 17 2024-05-10
20632 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ KSMO Á¦ 22Â÷ Ãá°èÁ¤±â½ÉÆ÷Áö¾ö ¹× ÃÑȸ : 2024-05-17 0 7 2024-05-10
20631 ÀÎõ 2024³âµµ Á¦47Â÷ ´ëÇѺ¹ºÎ¿µ»óÀÇÇÐȸ Çмú´ëȸ(1ÀÏÂ÷) : 2024-05-17 0 4 2024-05-10
20630 ºÎ»ê Á¦28Â÷ ¾Æ½Ã¾Æ-¿À¼¼¾Æ´Ï¾Æ »êºÎÀΰú¿¬¸Í Çмú´ëȸ (AOFOG 2024) (1ÀÏÂ÷) : 2024-05-17 0 6 2024-05-10
20629 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ ¿Â¶óÀÎ_¼­¿ï°æÀÎÁöȸ 276Â÷ ¿ù·ÊÁý´ãȸ : 2024-05-17 0 2 2024-05-10
20628 ¼­¿ï 2024³â ´ëÇѹ财Àå¾Ö¿ä½Ç±ÝÇÐȸ Ãá°è ½ÉÆ÷Áö¾ö : 2024-05-17 0 8 2024-05-10
20627 ´ëÀü ´ëÇÑ»êºÎÀΰúÀÇ»çȸ ´ëÀüÁöȸ ¿¬¼ö±³À° : 2024-05-17 0 13 2024-05-10
20626 ¼­¿ï ´ëÇѼҾƽÅÀåÇÐȸ (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-05-13 0 11 2024-05-10
20625 ´ëÀü Çѱ¹¿©ÀÚÀÇ»çȸ ´ëÀüÁöȸ 5¿ù Çмú½ÉÆ÷Áö¾ö(¾î±ú ÅëÁõ) : 2024-05-13 0 8 2024-05-10
20624 ¼­¿ï ´ëÇÑ·¹ÀÌÀúÇǺθð¹ßÇÐȸ Á¦46Â÷ Ãá°è Çмú´ëȸ : 2024-05-12 0 8 2024-05-10
20623 ¼­¿ï Á¦2ȸ ´ëÇѽŰæ°úÀÇ»çȸ Ãá°è ÀçÅÃÀÇ·á ½ÉÆ÷Áö¾ö : 2024-05-12 0 18 2024-05-10
20622 ´ë±¸ Á¦54ȸ ´ëÇѵΰæºÎ¿Ü°úÇÐȸ Áõ·ÊÇмú´ëȸ : 2024-05-11 0 8 2024-05-10
20621 °æºÏ 2024³â Á¦28ȸ ´ëÇÑÀü¸³¼±·¹ÀÌÀú¿¬±¸ÇÐȸ ÁýÁß½ÉÆ÷Áö¾ö : 2024-05-10 0 7 2024-05-10
20620 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼­¿ï¾Æ»êº´¿ø ´ç´¢º´ °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-30 0 161 2024-04-30
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷